sacituzumab + trastuzumab-vc-MMAE

Saci/Tras-vc-MMAE is a preclinical bispecific antibody-drug conjugate (bsADC) designed to simultaneously target Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast cell-surface antigen 2 (Trop-2). Developed by Biocytogen Pharmaceuticals, the drug utilizes a monovalent bispecific IgG1 framework incorporating the Fab fragments of trastuzumab (anti-HER2) and sacituzumab (anti-Trop-2). The antibody is conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a lysosomally cleavable valine-citrulline (vc) linker, with an average drug-to-antibody ratio (DAR) of 4.2. This dual-targeting approach is intended to enhance tumor cell binding and internalization, particularly in solid tumors with high Trop-2 expression and low-to-medium HER2 expression, potentially overcoming resistance and improving therapeutic efficacy compared to monospecific ADCs.

Other names

HER2 x Trop-2 bispecific antibody-drug conjugateHER-2 x Trop-2 bispecific antibody-drug conjugateHER 2 x Trop-2 bispecific antibody-drug conjugateHER2 x Trop-2 bsADCHER-2 x Trop-2 bsADCHER 2 x Trop-2 bsADC